Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on TearLab Corporation

Related TEAR
Manoj Venkiteshwar Joins TearLab As VP Of Medical Affairs
TearLab (TEAR) Enters Oversold Territory - Tale of the Tape

In a report published Monday, Canaccord Genuity reiterated its Buy rating on TearLab Corporation (NASDAQ: TEAR), and raised its price target from $6.00 to $8.00.

Canaccord Genuity noted, “Given strong underlying business trends, we increase our price target to $8 from $6 as we believe the growth profile of the stock justifies a higher multiple. In our opinion, TEAR should start benefitting from physician referrals (>500 IB), expanding sales force (12 reps and four managers), and robust lead activity from AAO conference.”

TearLab Corporation closed on Friday at $5.31.

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (TEAR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters